Core Points - Kalaris Therapeutics, Inc. has entered into a securities purchase agreement for a private placement, aiming to raise approximately $50.0 million before expenses [1][3] - The private placement includes participation from both new and existing institutional investors [2] - Kalaris plans to use the net proceeds to fund the clinical development of TH103 for neovascular AMD and for general corporate purposes [4] Financial Details - The private placement involves the sale of 4,200,000 shares of common stock at $10.00 per share and pre-funded warrants for 800,000 shares at $9.9999 each [3] - The pricing of the securities reflects a premium over the closing price of Kalaris' common stock over the previous five trading days [3] - The transaction is expected to close on or about December 19, 2025, pending customary closing conditions [3] Company Background - Kalaris Therapeutics is focused on developing treatments for prevalent retinal diseases and was founded by Dr. Napoleone Ferrara, known for his work in anti-VEGF therapy [8]
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Globenewswire·2025-12-17 22:59